Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes

S Sengupta, S Das, AC Crespo, AM Cornel, AG Patel… - Nature cancer, 2022 - nature.com
Apart from the anti-GD2 antibody, immunotherapy for neuroblastoma has had limited
success due to immune evasion mechanisms, coupled with an incomplete understanding of …
被引用次数：30 相关文章

Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes

S Sengupta, S Das, AC Crespo… - Nature …, 2022 - researchinformation.amsterdamumc …
Apart from the anti-GD2 antibody, immunotherapy for neuroblastoma has had limited
success due to immune evasion mechanisms, coupled with an incomplete understanding of …
[HTML] nih.gov

[HTML][HTML] Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes

S Sengupta, S Das, AC Crespo, AM Cornel… - Nature …, 2022 - ncbi.nlm.nih.gov
Apart from the anti-GD2 antibody, immunotherapy for neuroblastoma has had limited
success due to immune evasion mechanisms, coupled with an incomplete understanding of …

Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes

S Sengupta, S Das, AC Crespo, AM Cornel… - Nature …, 2022 - pubmed.ncbi.nlm.nih.gov
Apart from the anti-GD2 antibody, immunotherapy for neuroblastoma has had limited
success due to immune evasion mechanisms, coupled with an incomplete understanding of …

Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes.

S Sengupta, S Das, AC Crespo, AM Cornel… - Nature Cancer, 2022 - europepmc.org
Apart from the anti-GD2 antibody, immunotherapy for neuroblastoma has had limited
success due to immune evasion mechanisms, coupled with an incomplete understanding of …